ArticleThe American journal of case reports2026
A 73-Year-Old Man With a Late Isolated Brain Metastasis of Clear Cell Renal Cell Carcinoma Following a Durable Complete Response to Lenvatinib-Pembrolizumab, Resulting in Deferred Cytoreductive Nephrectomy.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND A durable complete response, or sustained disappearance of measurable malignancy, can occur in selected patients with metastatic renal cell carcinoma after systemic therapy. Clear cell renal cell carcinoma is the most common renal cell carcinoma subtype. Lenvatinib is a multikinase inhibitor with antiangiogenic activity, and pembrolizumab is an anti-programmed death-1 immune checkpoint inhibitor. Although this combination can induce deep extracranial responses, central nervous system relapse after prolonged complete response remains incompletely characterized. This report describes a 73-year-old man with late isolated brain metastasis of clear cell renal cell carcinoma after durable complete response to lenvatinib-pembrolizumab and deferred cytoreductive nephrectomy. CASE REPORT A 73-year-old man presented with right flank pain. Computed tomography showed a right renal tumor, level II inferior vena cava tumor thrombus, and multiple pulmonary metastases. Baseline brain computed tomography showed no intracranial metastasis. He received lenvatinib plus pembrolizumab, resulting in marked regression of the primary tumor, inferior vena cava thrombus, and lung metastases. Deferred cytoreductive nephrectomy with thrombectomy was then performed, and pathology confirmed clear cell renal cell carcinoma with extensive treatment effect. Lenvatinib was discontinued because of renal dysfunction, and pembrolizumab monotherapy was continued. The patient maintained complete extracranial radiographic remission for more than 2 years. He later developed headache, and brain magnetic resonance imaging revealed a solitary left occipital metastasis without systemic recurrence. Stereotactic body radiotherapy achieved local control. CONCLUSIONS This case shows that late isolated central nervous system relapse can occur despite durable extracranial complete response after lenvatinib-pembrolizumab and deferred cytoreductive nephrectomy. New neurological symptoms in long-term responders should prompt brain magnetic resonance imaging, because intracranial progression may occur even when systemic imaging remains negative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.